MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Welcome to this Pulsz referral code guide that’ll delve deeper into everything you need to know about this sweepstakes casino’s referral bonus. We’ll be taking a closer look at how easily you can ...
Executives now expect to spend between $28 billion and $29 billion through 2028 and see opportunities for at least $4 billion worth of projects that aren’t yet in their plans.... Visibility gaps in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback